Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the quarter ended March 31, 2014 and provided updates on key business priorities, including ongoing studies in cystic fibrosis (CF).
Vertex reported total first quarter 2014 revenues of $118 million, including revenues of $100 million from KALYDECO® (ivacaftor). The GAAP net loss for the first quarter of 2014 was $(232) million, or $(1.00) per share, including net charges of $81 million.
Help employers find you! Check out all the jobs and post your resume.
